Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence of Diabetes Mellitus and Its Impact on Outcomes in Patients Undergoing Surgical Pancreatectomy for Non-Malignant and Malignant Pancreatobiliary Diseases-A Retrospective Analysis.
Schranz A, Sternad C, Aziz F, Wagner D, Kornprat P, Sucher R, Jost PJ, Wölfler A, Pieber TR, Sourij H, Riedl JM, Aberer F. Schranz A, et al. Among authors: jost pj. J Clin Med. 2023 Dec 6;12(24):7532. doi: 10.3390/jcm12247532. J Clin Med. 2023. PMID: 38137600 Free PMC article.
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA, Moik F, Steinlechner S, Posch F, Mayer MC, Sandner AM, Berton F, Schlintl V, Koch L, John N, Wurm R, Pichler M, Bauernhofer T, Reimann P, Wohlkönig C, Richtig E, Winder T, Preusser M, Jost PJ, Ay C, Gerger A, Terbuch A, Riedl JM. Barth DA, et al. Among authors: jost pj. J Immunother Cancer. 2023 Dec 14;11(12):e007765. doi: 10.1136/jitc-2023-007765. J Immunother Cancer. 2023. PMID: 38097343 Free PMC article.
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.
Moik F, Riedl JM, Barth D, Berton F, Fink M, Englisch C, Hoeller C, Fuereder T, Ay L, Pabinger I, Richtig E, John N, Kostmann SM, Jost PJ, Gerger A, Terbuch A, Preusser M, Ay C. Moik F, et al. Among authors: jost pj. JACC CardioOncol. 2024 Nov 12;6(6):965-975. doi: 10.1016/j.jaccao.2024.09.007. eCollection 2024 Dec. JACC CardioOncol. 2024. PMID: 39801631 Free PMC article.
Prognostic impact of targetable driver alterations in resected early-stage lung cancer.
Terbuch A, Konjic S, Schlintl V, Absenger G, Jost PJ, Lindenmann J, Swatek P, John N, John T, Wurm R, Zacharias M, Posch F, Hochmair MJ, Fabikan H, Weinlinger C, Illini O, Horvath L, Gamerith G, Wolf D, Augustin F, Brcic L. Terbuch A, et al. Among authors: jost pj. Transl Lung Cancer Res. 2024 Nov 30;13(11):3096-3105. doi: 10.21037/tlcr-24-433. Epub 2024 Nov 14. Transl Lung Cancer Res. 2024. PMID: 39670019 Free PMC article.
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.
John N, Schlintl V, Sassmann T, Lindenmann J, Fediuk M, Wurm R, Douschan P, Zacharias M, Kalson L, Posch F, Absenger G, Brcic L, Jost PJ, Terbuch A. John N, et al. Among authors: jost pj. J Immunother Cancer. 2024 Apr 11;12(4):e008592. doi: 10.1136/jitc-2023-008592. J Immunother Cancer. 2024. PMID: 38604811 Free PMC article.
Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Fluhrer H, Hutterer GC, Golbeck S, Stidl M, Niedrist T, Pichler R, Mischinger J, Seles M, Mannweiler S, Spiegelberg J, Bauernhofer T, Jost PJ, Ahyai S, Zigeuner R, Pichler M, Barth DA. Fluhrer H, et al. Among authors: jost pj. Ther Adv Med Oncol. 2022 Nov 19;14:17588359221134065. doi: 10.1177/17588359221134065. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36425872 Free PMC article.
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification.
Tretter C, de Andrade Krätzig N, Pecoraro M, Lange S, Seifert P, von Frankenberg C, Untch J, Zuleger G, Wilhelm M, Zolg DP, Dreyer FS, Bräunlein E, Engleitner T, Uhrig S, Boxberg M, Steiger K, Slotta-Huspenina J, Ochsenreither S, von Bubnoff N, Bauer S, Boerries M, Jost PJ, Schenck K, Dresing I, Bassermann F, Friess H, Reim D, Grützmann K, Pfütze K, Klink B, Schröck E, Haller B, Kuster B, Mann M, Weichert W, Fröhling S, Rad R, Hiltensperger M, Krackhardt AM. Tretter C, et al. Among authors: jost pj. Nat Commun. 2023 Aug 2;14(1):4632. doi: 10.1038/s41467-023-39570-7. Nat Commun. 2023. PMID: 37532709 Free PMC article.
Elevated RIPK3 correlates with disease burden in myelofibrosis.
Dill V, Wagner CV, Keller EC, Fernandez-Hernandez FJ, Shoumariyeh K, Odinius TO, Buschhorn L, Hauch RT, Suren C, Hecker JS, Herhaus P, Sandherr M, Schmidt B, Slotta-Huspenina J, Bassermann F, Höckendorf U, Jilg S, Branca C, Vosberg S, Jost PJ. Dill V, et al. Among authors: jost pj. Blood Adv. 2023 Apr 11;7(7):1219-1224. doi: 10.1182/bloodadvances.2021006838. Blood Adv. 2023. PMID: 36453650 Free PMC article. No abstract available.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Koschmieder S, et al. Among authors: jost pj. Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. Ann Hematol. 2023. PMID: 36564535 Free PMC article. Clinical Trial.
112 results